newsfilter
← Earnings
Earnings Releases·

Beyond Air — Q3 2026 Earnings Summary

  • Revenue grew 28% year-over-year and 31% quarter-over-quarter to $2.3 million for the quarter ended September 30, 2026, while net loss narrowed to $7.8 million ($3.76 per share) from $7.9 million in the prior year period.
  • Management reaffirmed full-year 2026 revenue guidance of $8 million (excluding second-generation LungFit PH) and 2027 guidance of $16 million to $18 million, pending FDA approval expected in mid-December 2026.
  • The company executed a definitive agreement to sell its controlling interest in NeuroNOS Israel Ltd. to UNIVO Pharmaceutical Industries Ltd. and is transitioning its fiscal year-end to December 31 effective December 31, 2026.
  • Despite operating cash reserves of $18.5 million and reduced R&D expenses, the company cites substantial doubt regarding its ability to continue as a going concern due to a history of losses and reliance on securing financing to satisfy debt obligations.
Company
BEYOND AIR INC
Sector
Healthcare
Industry
Medical Devices